Bhowmick, Tanaya; Canton, Rafael; Pea, Federico; Quevedo, Juan; Santerre Henriksen, Anne; Timsit, Jean-François; Kaye, Keith S, Cefepime-enmetazobactam: first approved cefepime-β- lactamase inhibitor combination for multi-drug resistant Enterobacterales, «FUTURE MICROBIOLOGY», in corso di stampa, Online ahead of print, pp. 1 - 10 [Scientific article]Open Access
Trozzi, Ilaria; Giorgi, Beatrice; De Paola, Riccardo; Gatti, Milo; Pea, Federico, Accurate and Sensitive UHPLC–Tandem Mass Spectrometry Sequential Methods for Therapeutic Drug Monitoring of Aztreonam/Avibactam in Human Plasma, «PHARMACEUTICS», 2026, 10.3390/pharmaceutics18030377, pp. 1 - 15 [Scientific article]
Gatti, Milo; Rinaldi, Matteo; Laici, Cristiana; Ambretti, Simone; Siniscalchi, Antonio; Viale, Pierluigi; Pea, Federico, Biliary pharmacokinetic/pharmacodynamic analysis of continuous infusion ceftazidime–avibactam in a case series of orthotopic liver transplant recipients, «JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY», 2026, 81, Article number: dkag009 , pp. 1 - 5 [Scientific article]Open Access
Gatti, Milo; De Paola, Riccardo; Giorgi, Beatrice; Pea, Federico, Comparison of ceftolozane-tazobactam and ceftazidime-avibactam in the treatment of MDR/DTR
Pseudomonas aeruginosa
infections: a systematic review and meta-analysis, «CLINICAL INFECTIOUS DISEASES», 2026, 10.1093/cid/ciag194, pp. 1 - 23 [Scientific article]
Soriano, Alex; Tascini, Carlo; Falcone, Marco; Morata, Laura; Bongiovanni, Marco; Pea, Federico; Viale, Pierluigi, Evaluating oritavancin for Gram-positive infections: a systematic review of on-label and off-label use, «DRUGS IN CONTEXT», 2026, 15, Article number: 202594 , pp. 1 - 18 [Scientific article]Open Access
Cojutti, Pier Giorgio; Pascale, Renato; Grechi, Andrea; Ambretti, Simone; Viale, Pierluigi; Pea, Federico, Pharmacokinetic/Pharmacodynamic Analysis of High-Dose Daptomycin in Combination with Continuous Infusion Ceftobiprole in a Case Series of Documented Staphylococcal Bacteremia or Endocarditis: Is There Any Room for TDM-Guided Dosing Reduction?, «ANTIBIOTICS», 2026, 10.3390/antibiotics15030315, pp. 1 - 15 [Scientific article]
Gatti, Milo; Pea, Federico, Pharmacological approaches to overcome antimicrobial resistance to novel beta-lactams in MDR Gram-negative bacterial infections: Current practice and future directions, «EXPERT OPINION ON PHARMACOTHERAPY», 2026, 10.1080/14656566.2026.2651279, pp. 1 - 19 [Scientific article]
Gatti, Milo; Pea, Federico, Raising the Bar of PK/PD Target Attainment of Beta-Lactams in Daily Clinical Practice: An Effective Strategy to Overcome Resistance Development to Novel Beta-Lactams?, «INFECTIOUS DISEASE REPORTS», 2026, 18, Article number: 3 , pp. 1 - 4 [Scientific article]Open Access
Gatti, Milo; Pea, Federico, Real-World Evidence and Multidrug Resistant Infections: How Can We Leverage RWE to Improve Patient Outcome with the Novel Beta-Lactam and Beta-Lactam/Beta-Lactamase Inhibitor Combinations, «INFECTION AND DRUG RESISTANCE», 2026, Volume 19, pp. 1 - 23 [Scientific article]
Trozzi, Ilaria; Giorgi, Beatrice; De Paola, Riccardo; Gatti, Milo; Pea, Federico, Two Comprehensive Liquid Chromatography High-Resolution Mass Spectrometry (UPLC-MS/MS) Multi-Methods for Real-Time Therapeutic Drug Monitoring (TDM) of Five Novel Beta-Lactams and of Fosfomycin Administered by Continuous Infusion, «PHARMACEUTICS», 2026, 18, Article number: 91 , pp. 1 - 20 [Scientific article]Open Access
Di Bella, Stefano; Geremia, Nicholas; Pea, Federico; Zeitlinger, Markus; Sanson, Gianfranco; Monticelli, Jacopo; Bergmann, Felix; Motet, Christian; Lambotte-Buffet, Christophe; Zerbato, Verena; Gatti, Milo, When and How to Use Subcutaneous Antibiotics, «CLINICAL INFECTIOUS DISEASES», 2026, 10.1093/cid/ciaf691, pp. 1 - 12 [Scientific article]
Gatti, Milo; Rinaldi, Matteo; Cojutti, Pier Giorgio; Bonazzetti, Cecilia; Siniscalchi, Antonio; Tonetti, Tommaso; Ambretti, Simone; Tedeschi, Sara; Giannella, Maddalena; Viale, Pierluigi; Pea, Federico, A pre-post quasi-experimental study of antimicrobial stewardship exploring the impact of a multidisciplinary approach aimed at attaining an aggressive joint pharmacokinetic/pharmacodynamic target with ceftazidime/avibactam on treatment outcome of KPC-producing Klebsiella pneumoniae infections and on ceftazidime/avibactam resistance development, «ANTIMICROBIAL AGENTS AND CHEMOTHERAPY», 2025, 69, pp. 1 - 12 [Scientific article]Open Access
Gatti, M.; Rinaldi, M.; Bonazzetti, C.; Siniscalchi, A.; Tonetti, T.; Ambretti, S.; Giannella, M.; Viale, P.; Pea, F., A pre-post quasi-experimental study of the impact of TDM-guided aggressive pharmacokinetic/pharmacodynamic target attainment of continuous infusion ceftolozane/tazobactam monotherapy in treating severe Pseudomonas aeruginosa infections: A strategy useful for raising the bar?, «JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY», 2025, 80, pp. 1543 - 1551 [Scientific article]Open Access
Cheng, Lucy; Kumar, Suchita; Cojutti, Pier Giorgio; Pea, Federico; Tang Girdwood, Sonya; Morales Junior, Ronaldo, Can a population pharmacokinetics model built on intermittent infusions accurately predict meropenem concentrations in children receiving continuous infusions?, «BRITISH JOURNAL OF CLINICAL PHARMACOLOGY», 2025, 10.1002/bcp.70376, pp. 1 - 6 [Scientific article]
Cojutti, Pier Giorgio; Tedeschi, Sara; Zamparini, Eleonora; Fornaro, Giacomo; Zagarrigo, Manuel; De Paolis, Massimiliano; Viale, Pierluigi; Pea, Federico, Could a Reduced Dose of 8 g of Continuous Infusion Fosfomycin Be Considered as Effective as and Safer than a Standard 16 g Dose When Combined with High-Dose Daptomycin in the Treatment of Staphylococcal osteoarticular Infections?, «ANTIBIOTICS», 2025, 14, Article number: 139 , pp. 1 - 14 [Scientific article]Open Access
